

**Saturday, 21 January 2023**

<b>09:25 – 09:30</b>	<b>Welcome and Overview of Working Party</b>	Donal McLornan (United Kingdom) Joanna Drozd-Sokolowska (Poland)
<b>09:30 – 10:20</b>	<b>Session I: A dynamic landscape: An update on classification and prognostication in Myelodysplastic Syndrome in 2023</b> <i>Chairs: Marie Robin (France) and Donal McLornan (United Kingdom)</i>	
09:30 – 09:45	Update on Myelodysplastic Syndrome classification schemes in 2023 – progress and challenges	Marie Robin (France)
09:45 – 10:00	The IPSS-Molecular: A new molecular era in Myelodysplastic Syndrome prognostication- IPSS-M	Matteo Della Porta (Italy)
10:00 – 10:10	The IPSS-Molecular: Utilising IPSS-M to guide transplantation decisions/ predict outcome. What do we know?	Nico Gagelmann (Germany)
10:10 – 10:20	Q&A	

**10:20 – 10:30 Break**

<b>10:30 – 11:40</b>	<b>Session II: Improving Transplantation Outcomes for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in 2023</b> <i>Chairs: Francesco Onida (Italy) and Joanna Drozd-Sokolowska (Poland)</i>	
10:30 – 10:50	Pre-treatment before allo-HCT for in Myelodysplastic Syndrome in the era of novel agents	Case for Yes: Pierre Fenaux (France) Case for No: Katja Sockel (Germany)
10:50 – 11:10	Conditioning for Myelodysplastic Syndrome: a transatlantic debate on optimal strategies	US Practice: Bart Scott (USA) EU Practice: Nicolaus Kroger (Germany)
11:10 – 11:30	Chronic Myelomonocytic Leukaemia: All transplant eligible patients should be offered Allo-HCT	Case for Yes: Joanna Drozd-Sokolowska (Poland) Case for No: Francesco Onida (Italy)
11:30 – 11:40	Q&A	

**11:40 – 12:00 Break**

<b>12:00 – 12:25</b>	<b>Session III: State of the Art Approaches to Allo-HCT for MDS</b> <i>Chairs: Patrick Hayden (Ireland) and Yves Chalandon (Switzerland)</i>	
	Post Transplant Intervention to improve Outcomes post Allo-HCT for MDS	Ibrahim Yakoub-Agha (France)

**12:25 – 12:50 Break**

<b>12:50 - 13:35</b>	<b>Session IV: VEXAS, a multidisciplinary team united</b> <i>Chairs: Christof Scheid (Germany) and Meral Beksac (Turkey)</i>	
12:50 – 13:00	The point of view of the rheumatologist on role of allo-HCT	Arsene Mekinian (France)
13:00 – 13:10	Allo-HCT in Myelodysplastic Syndrome /VEXAS association	Carmelo Gurnari (Italy)
13:10 – 13:20	Allo-SCT in VEXAS without Myelodysplastic Syndrome	Rafaella Greco (Italy)
13:20 – 13:30	Case presentation: Upfront allo-HCT in VEXAS	Moniek de Witte (Netherlands)
13:30 – 13:45	Q&A	